CorMedix to acquire Melinta for $300M; Q2 revenue $39.7M, net income $19.8M

CorMedix Inc.

Enters agreement to acquire Melinta for $260M cash + $40M stock, plus contingent milestone payments up to $25M and tiered royalties on REZZAYO and MINOCIN.
Acquisition funded by existing cash and $150M convertible notes at 4.00% due 2030; expects closing in September 2025.
Q2 2025 net revenue $39.7M (vs $0.8M YoY); net income $19.8M ($0.29 EPS) vs net loss $14.2M in Q2 2024.
Adjusted EBITDA Q2 2025 $22.4M; operating expenses $18.3M up 18% YoY driven by G&A and R&D.
Contingent payments up to $25M if FDA approves REZZAYO for prophylaxis in stem cell transplant by June 2029.

item 1.01item 2.02item 3.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.